A unique GPCR company
dedicated to Immuno-Oncology
Our mission: delivering game-changing immunotherapies
We are committed to improve patients’ life and to support physicians by delivering innovative immunotherapies to fight cancer.
Our vision: unveiling the immune potential of GPCR
We aim at making an impactful difference for patients suffering from cancer by discovering first-in-class and best-in-class treatments to tackle GPCR-mediated immunosuppression.
Leveraging our expertise, innovative approach and proprietary platform, we develop a unique pipeline in immune-oncology and progress our most advanced programs towards the clinic.
Over the last decade, the company has also created a proprietary pipeline of GPCR-based programs in neurology and rare diseases. Domain is securing the development of these first-in-class assets by establishing early partnerships.
Our business model: corporate development and partnership
Domain Therapeutics is creating value for its shareholders by bringing to the clinic its proprietary portfolio of programs in immuno-oncology and by creating early partnerships on other assets in other non immuno-oncology therapeutic area.